Tildacerfont Evaluated in Two Phase 2 Open-Label Studies in Adults with Classic Congenital Adrenal Hyperplasia

August 4, 2021

Patients with classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21OHD) may benefit from the drug tildacerfont, according to the results from two Phase 2 clinical studies recently published in The Journal of Clinical Endocrinology & Metabolism. Researchers led by Chris N. Barnes, PhD, of Spruce Biosciences (who funded the trial), point out that […]

To view the full Member Resource, please Log in

TOPICS IN THIS ARTICLE:

Adrenal Product / Technology

←Endocrine Society Priorities Included in Appropriations Legislation Advancing in House

Endocrine Society Discusses ARPA-H with Congress, NIH, and OSTP→

View Archives

Join the Global Movement Advancing Endocrine Science and Medicine

Become a part of a community of 18,000-plus endocrine investigators and clinicians who conduct research and provide quality patient care in more than 100 countries. Advance your career and the field of endocrinology through our many educational, leadership and advocacy opportunities.

Join Today